Skip to main content
. 2015 Mar 10;6(10):8144–8154. doi: 10.18632/oncotarget.3519

Figure 2. MAPKBP1high is associated with unfavourable treatment.

Figure 2

(A) EFS and (B) OS in the entire cohort of 157 CN-AML cases.